XRP price flashed a gravestone doji after a $1.35-$1.65 rally, signaling potential reversal. Analysts target $0.80-$0.91 based on the 200-week EMA loss and Gaussian Channel, while key resistance sits at $2.10-$2.14.
Deutsche Bank upgraded Merck to Buy and raised its price target to $150 from $115, citing a clear path beyond Keytruda’s patent expiration. Merck meanwhile forecast 2026 revenue of $65.5 billion to $67.0 billion and said it faces a $2.5 billion headwind this year.
AstraZeneca announced positive Phase III trial results for Breztri Aerosphere in uncontrolled asthma patients, showing statistically significant improvements over dual-combination therapies. Deutsche Bank maintained a Sell rating with a £115 price target.
